Clinical trial
Aminocamptothecin in Treating Patients With Recurrent or Unresectable Epithelial…
NCT00002671 · NYU Langone Health, Other · Completed
Key facts
| NCT number | NCT00002671 |
|---|---|
| Title | Aminocamptothecin in Treating Patients With Recurrent or Unresectable Epithelial Ovarian Cancer |
| Official title | PHASE II STUDY OF 9-20-S-AMINO-CAMPTOTHECIN (9-AC) AS SECOND LINE THERAPY IN ADVANCED OVARIAN CARCINOMA |
| Lead sponsor | NYU Langone Health, Other |
| Collaborators | National Cancer Institute (NCI) NIH Eastern Cooperative Oncology Group |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Cancer |
| Intervention type | Drug |
| Interventions | aminocamptothecin |
| Start date | Dec 1, 1995 |
| Primary completion | Feb 1, 2001 |
| First posted | May 24, 2004 |
| Last update posted | Nov 9, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: